Literature DB >> 27035428

Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells.

Kamila Domińska1, Tomasz Ochędalski1, Karolina Kowalska1, Zuzanna Elżbieta Matysiak-Burzyńska1, Elżbieta Płuciennik2, Agnieszka Wanda Piastowska-Ciesielska1.   

Abstract

Deregulation of locally secreted hormones, such as angiotensin II (Ang II) and relaxin 2 (RLN2), has been linked to a higher risk of select cancers or a poor prognosis in patients. In this study, for the first time a common effect of Ang II and RLN2 in relation to various aspects of prostate cancer development and metastasis are presented. Four independent colorimetric assays were used to analyze cell viability and proliferation. The changes of cell adhesion to extracellular matrix proteins and invasion/aggressiveness ability of prostate cancer cells (LNCaP, PC3) before and after peptides treatment, were also investigated. The findings suggest that the both investigated systems, have an impact on cell growth/division or spread, to some degree via overlapping signal transduction pathways. Intermediate or sometimes poorer results were achieved by using a combination of both hormones than when each was used individually. It seems that Ang II and RLN2 can play a significant role in increasing the aggressiveness of prostate tumors by up-regulating BIRC5 expression and MMP-2 and MMP-9 secretion. In addition, we speculate that Ang II and RLN2 are involved in the transition from the androgen-dependent to the androgen-independent phenotype via modulation of the expression of androgen receptors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27035428     DOI: 10.3892/ijo.2016.3458

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Relaxin-like peptides in male reproduction - a human perspective.

Authors:  Richard Ivell; Alexander I Agoulnik; Ravinder Anand-Ivell
Journal:  Br J Pharmacol       Date:  2017-02-27       Impact factor: 8.739

2.  Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Authors:  A Aragón-Herrera; S Feijóo-Bandín; D Rodríguez-Penas; E Roselló-Lletí; M Portolés; M Rivera; M Bigazzi; D Bani; O Gualillo; J R González-Juanatey; F Lago
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

Review 3.  The Effect of Local Renin Angiotensin System in the Common Types of Cancer.

Authors:  Moudhi Almutlaq; Abir Abdullah Alamro; Hassan S Alamri; Amani Ahmed Alghamdi; Tlili Barhoumi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-03       Impact factor: 5.555

4.  BRAFV600E, hypothyroidism, and human relaxin in thyroid carcinogenesis.

Authors:  Brenda Y Hernandez; Mobeen Rahman; Lenora W M Loo; Owen T M Chan; David Horio; Shane Morita; Gillian Bryant-Greenwood
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-29       Impact factor: 4.322

5.  Angiotensin 1-7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer.

Authors:  Kamila Domińska; Piotr Okła; Karolina Kowalska; Dominika Ewa Habrowska-Górczyńska; Kinga Anna Urbanek; Tomasz Ochędalski; Agnieszka Wanda Piastowska-Ciesielska
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

6.  The Impact of Ang-(1-9) and Ang-(3-7) on the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes.

Authors:  Kamila Domińska; Karolina Kowalska; Kinga Anna Urbanek; Dominika Ewa Habrowska-Górczyńska; Tomasz Ochędalski; Agnieszka Wanda Piastowska Ciesielska
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

7.  CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.

Authors:  Hanqi Lei; Zifeng Wang; Donggen Jiang; Fang Liu; Meiling Liu; Xinxing Lei; Yafei Yang; Bin He; Min Yan; Hai Huang; Quentin Liu; Jun Pang
Journal:  Cell Death Dis       Date:  2021-07-27       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.